$2.510
0.000 (0.00%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
KPRX Prediction & Forecast by Similar Chart Analysis
Alphio's KPRX stock price prediction model matches the current Kiora Pharmaceuticals Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $2.42 (-3.77%). The 1-week path is $2.31 (-7.82%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy Kiora Pharmaceuticals Inc Stock?
Kiora Pharmaceuticals Inc is currently not a strong buy due to its recent financial losses and lack of profitability. The stock price is at $2.62, with a forward P/E ratio of 2.41, indicating potential undervaluation, but the company has reported a loss of $0.58 per share in Q1 2026. The RSI is at 49.46, suggesting the stock is neither overbought nor oversold, which means it may not be the best time to buy. The main risk is the negative earnings trend, with a projected EPS of -0.34 for the last quarter, indicating ongoing financial challenges.
KPRX stock price ended at $2.51 on Tuesday, after rising 0.00%
Kiora Pharmaceuticals Inc (KPRX) last closed at $2.51, gaining +0.00%. These facts feed the 1-day and 1-week KPRX price prediction above.
Forecast Drivers
Kiora Pharmaceuticals Inc (KPRX) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bearish
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bullish
Similar Chart Patterns
Stocks whose recent price path most closely matches KPRX, ranked by similarity.
Seasonality analysis for KPRX
Historically the probability of a positive September return for KPRX is 2.38%. February offers the highest probability of a positive month at 75.86%, while October is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.